European public assessment reports

  • Email
  • Help

This page allows you to find the European public assessment reports (EPAR) for human medicines published by the European Medicines Agency (EMA).

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

Use this search to find information including a public-friendly summary in question-and-answer format and the package leaflet. You can also find information on medicines that have been refused a marketing authorisation or that have been suspended or withdrawn after being approved.

As of October 2016, EMA publishes the clinical data submitted by pharmaceutical companies to support their marketing applications for human medicines under the centralised procedure, allowing the public to better understand the Agency’s decision-making. For more information see clinical data publication.

The Agency does not evaluate all medicines currently in use in Europe. If you cannot find the medicine you need through this search, please visit the website of your national health authority.

More information is available on the Central authorisation procedure and in EPARs: background and context.

Document status

Include:

Browse by letter

Browse by letter for medicines that have a European Public Assessment Report:

Or for other types of content pick from the navigation on the left.

Search by keyword

Search for keyword:

Search by therapeutic area

Browse the database based on therapeutic area:

/

Browse by type

Browse by type:

Download results to spreadsheet
EPAR Search results
Name Active substance Therapeutic area Date of authorisation / refusal Additional monitoring Orphan     Has current safety alert Status
Arzerra

ofatumumab

Leukemia, Lymphocytic, Chronic, B-Cell 2010-04-19           Authorised
Atriance

nelarabine

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2007-08-22           Authorised
Besponsa

inotuzumab ozogamicin

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2017-06-29           Authorised
Blincyto

blinatumomab

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2015-11-23           Authorised
Ceplene

histamine dihydrochloride

Leukemia, Myeloid, Acute 2008-10-07           Authorised
Dacogen

decitabine

Leukemia, Myeloid 2012-09-20           Authorised
Evoltra

clofarabine

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2006-05-29           Authorised
Gazyvaro

obinutuzumab

Leukemia, Lymphocytic, Chronic, B-Cell 2014-07-23           Authorised
Glivec

imatinib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell Lymphoblastic Leukemia-Lymphoma 2001-11-07           Authorised
Iclusig

ponatinib

Leukemia, Lymphoid Leukemia, Myeloid 2013-07-01           Authorised
Imatinib Accord

imatinib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell Lymphoblastic Leukemia-Lymphoma 2013-07-01           Authorised
Imatinib Actavis

imatinib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell Lymphoblastic Leukemia-Lymphoma 2013-04-17           Authorised
Imatinib medac

imatinib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell Lymphoblastic Leukemia-Lymphoma 2013-09-25           Authorised
Imatinib Teva

imatinib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell Lymphoblastic Leukemia-Lymphoma 2013-01-08           Authorised
Imbruvica

ibrutinib

Leukemia, Lymphocytic, Chronic, B-Cell 2014-10-21           Authorised
IntronA

interferon alfa-2b

Leukemia, Hairy Cell Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2000-03-09           Authorised
Jylamvo

methotrexate

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2017-03-29           Authorised
Litak

cladribine

Leukemia, Hairy Cell 2004-04-14           Authorised
MabThera

rituximab

Leukemia, Lymphocytic, Chronic, B-Cell 1998-06-02           Authorised
Noxafil

posaconazole

Aspergillosis Candidiasis Coccidioidomycosis Mycoses 2005-10-25           Authorised
Oncaspar

pegaspargase

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2016-01-14           Authorised
Spectrila

asparaginase

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2016-01-14           Authorised
Sprycel

dasatinib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell Lymphoblastic Leukemia-Lymphoma 2006-11-20           Authorised
Tasigna

nilotinib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2007-11-19           Authorised
Trisenox

arsenic trioxide

Leukemia, Promyelocytic, Acute 2002-03-05           Authorised